RBM: Outlook for 2016 (Video)

The film unites Risk-based Monitoring (RBM) experts from a sponsor side, contract research organization, strategic advisers and technology providers. The experts provide outlook for Risk-based Monitoring for 2016:

Dr. María Proupín-Pérez, PMP – Project Leader (PPH plus)
Dr. Peter Schiemann – Managing Partner (Widler & Schiemann Ltd.)
Moe Alsumidaie – Chief Data Scientist (Annex Clinical)
Dr. Johann Proeve – Freelance Consultant (Clinical Data Management)
Dr. Artem Andrianov – CEO (Cyntegrity)

Asked Questions:
– At what stage does RBM stay now?
– How will RBM develop in 2016?
– What do you wish in 2016?

Interested in learning more about Cyntegrity and our services?

About Cyntegrity

By |2016-11-16T18:35:37+00:00January 15, 2016|Blog|0 Comments

About the Author:

Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.

Leave A Comment

Upcoming Events

  1. PCT Europe 2018

    November 28 - November 29

Register Today!

Get Free Test Access